hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

hVIVO PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Current Portion of Long-Term Debt
ÂŁ1.4m
CAGR 3-Years
-12%
CAGR 5-Years
48%
CAGR 10-Years
24%
Oxford Nanopore Technologies PLC
LSE:ONT
Current Portion of Long-Term Debt
ÂŁ4.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Current Portion of Long-Term Debt
ÂŁ146k
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Current Portion of Long-Term Debt
ÂŁ129k
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Current Portion of Long-Term Debt
ÂŁ1.6m
CAGR 3-Years
-7%
CAGR 5-Years
170%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Current Portion of Long-Term Debt
ÂŁ253k
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.4m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Current Portion of Long-Term Debt amounts to 1.4m GBP.

What is hVIVO PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
24%

Over the last year, the Current Portion of Long-Term Debt growth was -5%. The average annual Current Portion of Long-Term Debt growth rates for hVIVO PLC have been -12% over the past three years , 48% over the past five years , and 24% over the past ten years .

Back to Top